4.7 Article

Discovery and validation of breast cancer subtypes

期刊

BMC GENOMICS
卷 7, 期 -, 页码 -

出版社

BMC
DOI: 10.1186/1471-2164-7-231

关键词

-

资金

  1. NCI NIH HHS [U01 CA085129, U01CA85129] Funding Source: Medline
  2. NHLBI NIH HHS [N01-HV-28183, N01HV28183] Funding Source: Medline

向作者/读者索取更多资源

Background: Previous studies demonstrated breast cancer tumor tissue samples could be classified into different subtypes based upon DNA microarray profiles. The most recent study presented evidence for the existence of five different subtypes: normal breast-like, basal, luminal A, luminal B, and ERBB2(+). Results: Based upon the analysis of 599 microarrays (five separate cDNA microarray datasets) using a novel approach, we present evidence in support of the most consistently identifiable subtypes of breast cancer tumor tissue microarrays being: ESR1(+)/ERBB2-, ESR1-/ERBB2-, and ERBB2(+) ( collectively called the ESR1/ERBB2 subtypes). We validate all three subtypes statistically and show the subtype to which a sample belongs is a significant predictor of overall survival and distant-metastasis free probability. Conclusion: As a consequence of the statistical validation procedure we have a set of centroids which can be applied to any microarray (indexed by UniGene Cluster ID) to classify it to one of the ESR1/ERBB2 subtypes. Moreover, the method used to define the ESR1/ERBB2 subtypes is not specific to the disease. The method can be used to identify subtypes in any disease for which there are at least two independent microarray datasets of disease samples.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据